Experimental Drug Derived From Krill Oil Does Not Appear More Effective Than Placebo For Reducing Triglyceride Levels In Phase 3 Trial

reports Acasti Pharma announced that its drug CaPre, which is derived from krill oil, “failed to beat placebo by a large margin in reducing a type of fat found in blood that increases the risk of heart diseases” in a phase 3 trial. The company said that the drug appeared to reduce triglyceride, but not significantly more than placebo. https://www.reuters.com/article/us-acasti-pharma-study/acastis-krill-oil-derived-drug-fails-late-stage-study-shares-tumble-idUSKBN1ZC10A